Read the following texts and table with financial data from an S&P 500 earnings report carefully.Based on the question-answer history (if provided), answer the last question. The answer may require mathematical calculation based on the data provided.


( a ) excludes discontinued operations . ( b ) earnings before interest expense and taxes as a percent of average total assets . ( c ) total debt as a percent of the sum of total debt , shareholders 2019 equity and non-current deferred income tax liabilities . the results above include the impact of the specified items detailed below . additional discussion regarding the specified items in fiscal years 2017 , 2016 and 2015 are provided in item 7 . management 2019s discussion and analysis of financial condition and results of operations. . <table class='wikitable'><tr><td>1</td><td>millions of dollars except per share amounts</td><td>years ended september 30 2017</td><td>years ended september 30 2016</td><td>years ended september 30 2015</td><td>years ended september 30 2014</td><td>years ended september 30 2013</td></tr><tr><td>2</td><td>total specified items</td><td>$ 1466</td><td>$ 1261</td><td>$ 1186</td><td>$ 153</td><td>$ 442</td></tr><tr><td>3</td><td>after-tax impact of specified items</td><td>$ 971</td><td>$ 892</td><td>$ 786</td><td>$ 101</td><td>$ 279</td></tr><tr><td>4</td><td>impact of specified items on diluted earnings per share</td><td>$ -4.34 ( 4.34 )</td><td>$ -4.10 ( 4.10 )</td><td>$ -3.79 ( 3.79 )</td><td>$ -0.51 ( 0.51 )</td><td>$ -1.40 ( 1.40 )</td></tr><tr><td>5</td><td>impact of dilution from share issuances</td><td>$ -0.54 ( 0.54 )</td><td>$ 2014</td><td>$ -0.02 ( 0.02 )</td><td>$ 2014</td><td>$ 2014</td></tr></table> item 7 . management 2019s discussion and analysis of financial condition and results of operations the following commentary should be read in conjunction with the consolidated financial statements and accompanying notes . within the tables presented throughout this discussion , certain columns may not add due to the use of rounded numbers for disclosure purposes . percentages and earnings per share amounts presented are calculated from the underlying amounts . references to years throughout this discussion relate to our fiscal years , which end on september 30 . company overview description of the company and business segments becton , dickinson and company ( 201cbd 201d ) is a global medical technology company engaged in the development , manufacture and sale of a broad range of medical supplies , devices , laboratory equipment and diagnostic products used by healthcare institutions , life science researchers , clinical laboratories , the pharmaceutical industry and the general public . the company's organizational structure is based upon two principal business segments , bd medical ( 201cmedical 201d ) and bd life sciences ( 201clife sciences 201d ) . bd 2019s products are manufactured and sold worldwide . our products are marketed in the united states and internationally through independent distribution channels and directly to end-users by bd and independent sales representatives . we organize our operations outside the united states as follows : europe ; ema ( which includes the commonwealth of independent states , the middle east and africa ) ; greater asia ( which includes japan and asia pacific ) ; latin america ( which includes mexico , central america , the caribbean , and south america ) ; and canada . we continue to pursue growth opportunities in emerging markets , which include the following geographic regions : eastern europe , the middle east , africa , latin america and certain countries within asia pacific . we are primarily focused on certain countries whose healthcare systems are expanding , in particular , china and india . strategic objectives bd remains focused on delivering sustainable growth and shareholder value , while making appropriate investments for the future . bd management operates the business consistent with the following core strategies : 2022 to increase revenue growth by focusing on our core products , services and solutions that deliver greater benefits to patients , healthcare workers and researchers; .
Question: what was the value of total specified items as of 9/30/17?
Answer: 1466.0
Question: and the after-tax impact of specified items for that period?

971.0